Please login to the form below

Not currently logged in
Email:
Password:

blood cancer

This page shows the latest blood cancer news and features for those working in and with pharma, biotech and healthcare.

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Settlement clears path for Biogen, Samsung’s Humira biosimilar

The company has made strenuous efforts to diversify into areas such as cancer, and has high hopes for new launches such as blood cancer therapies Imbruvica (ibrutinib) and Venclexta (venetoclax).

Latest news

  • FDA turns down Celgene’s filing for multiple sclerosis drug FDA turns down Celgene’s filing for multiple sclerosis drug

    Ozanimod was acquired by Celgene as part of its $7.2bn takeover of Receptos in 2015, part of a drive to expand its business beyond cancer, a view reiterated by Celgene ... Celgene has had a difficult few months, with the latest knock coming after its

  • Celgene’s triple multiple myeloma therapy clears phase III trial Celgene’s triple multiple myeloma therapy clears phase III trial

    US biotech Celgene has been a big player in the blood cancer space, most recently securing CHMP backing to expand its biggest-selling drug Revlimid as a maintence treatment for multiple

  • Amgen set for Kyprolis label boost after CHMP backing Amgen set for Kyprolis label boost after CHMP backing

    The disease itself is as a rare, incurable blood cancer, characterised by the recurring pattern of remission and relapse and accounting for one percent of all cancers. ... According to Globocan, a project for cancer research, approximately 39, 000

  • Celgene reaches $9bn agreement to buy Juno Celgene reaches $9bn agreement to buy Juno

    Celgene reaches $9bn agreement to buy Juno. Acquires its blood cancer CAR-T candidate in the process. ... lymphoma (DLBCL) and according to Celgene could become a $3bn product if approved in multiple blood cancer indications.

  • Unsure on efficacy, NICE passes J&J’s Darzalex to CDF Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

    Unsure on efficacy, NICE passes J&J’ s Darzalex to CDF. The bone marrow cancer therapy is now temporarily approved as a fourth-line treatment. ... who have failed other drugs for the blood cancer, promoting J&J to ask for a review of fourth-line use.

More from news
Approximately 9 fully matching, plus 205 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2015 Deal Watch December 2015

    Also during the month AstraZeneca announced the acquisition of 55% for $4bn of Acerta which has a BTK inhibitor in phase III for blood cancer. ... Acerta has phase III BTK inhibitor for blood cancer. 4, 000.

  • Taking a strategic approach Taking a strategic approach

    proposed submitting further evidence and an amended patient access scheme for its prostate cancer drug. ... In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    485. AstraZeneca/Celgene. Exclusive collaboration. MEDI4736 - an investigational checkpoint inhibitor in serious blood cancers. ... 85. Agios Pharmaceuticals / Celgene. R&D collaboration and profit share. AG-881 IDH (isocitrate dehydrogenase) mutant

  • Pharma deals during April 2014 Pharma deals during April 2014

    Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer); ... which comes off patent

  • NICE and ‘ultra orphans’ NICE and ‘ultra orphans’

    It won't, for example, affect medicines such as Novartis' treatment for myelofibrosis, a rare blood cancer of which there are only around 0.4 cases of the condition per 100, ... NICE, however, has been asked to consider its use to treat atypical

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Increasing the speed of knowledge sharing in blood cancer to improve patient care

    Increasing the speed of knowledge sharing in blood cancer to improve patient care. ... Spring has sprung and the blood cancer congress calendar is jam-packed with news, science, education and knowledge sharing opportunities.

  • THE OTHER SIDE OF...BLOOD CANCER

    participant. THE OTHER SIDE OF … BLOOD CANCER. “ I’ m so sick of chasing him down the hospital corridors. ... The environment is certainly one challenge – busy hospital, many blood cancer patients, so her doctor’ s time is limited.

  • Cancer communications; it's in our blood

    Cancer communications; it's in our blood. We have years of experience working in cancer communications, partnering with some of the biggest brands, institutions and societies. ... From solid tumours to blood cancer, from patients to professionals; within

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics